Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

By M. Hanefeld, M. Çağatay, T. Petrowitsch, D. Neuser, D. Petzinna, M. Rupp. European Heart Journal, 2004

650 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. (2005, background): “on such oral drugs as alphaglucosidase inhibitors [48-50], short-term insulin secretagogues [51-57], rapid insulin analogs [58, 59] and such potential interesting candidates for diabetes therapy as incretin hormones [60-62].”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Clinical trials have shown CVD benefit in patients with impaired glucose tolerance and diabetes (64,114).”
Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). (2015, positive): “A meta-analysis of 7 clinical trials using acarbose con ﬁ rmed the reduction in cardiovascular events and risk factors, including triglycerides, blood pressure and body weight [33].”
Postprandial hyperglycemia and diabetes complications: is it time to treat? (2005, background): “Furthermore, in a recent meta-analysis of type 2 diabetic patients, acarbose treatment was associated with a significant reduction in cardiovascular events, even after adjusting for other risk factors (29).”